{"ticker": {"uuid": "f6db1008-c56f-44d2-9216-b4268cb66ffa", "symbol": "MRK", "name": "Merck & Company Inc", "exchange": "NYSE", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - General"}, "articles": [{"title": "Merck Expands TL1A Lead With Positive Tulisokibart Results In UC", "summary": "Merck has announced positive results for its drug Tulisokibart in ulcerative colitis trials, further strengthening its leadership in the TL1A drug class. This development highlights Merck's expanding pipeline in immunology and potentially impacts future treatment strategies for i", "url": "https://insights.citeline.com/scrip/r-and-d/clinical-trials/merck-expands-tl1a-lead-with-positive-tulisokibart-results-in-uc-6G3T6ZR4KFDPZPCM4FAAWNQWVY/", "source_name": "Citeline News & Insights", "published_at": "2026-06-22T19:30:19", "published_display": "22 Jun 2026 19:30", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck Scores Key Phase 3 Win For Novel Ulcerative Colitis Therapy", "summary": "Merck & Co. announced positive results from its Phase 3 ATLAS-UC induction study for tulisokibart, a novel anti-TL1A therapy for ulcerative colitis. The drug met its primary endpoint of clinical remission at week 12 and key secondary endpoints, with a safety profile consistent wi", "url": "https://www.benzinga.com/news/health-care/26/06/60024141/merck-scores-key-phase-3-win-for-novel-ulcerative-colitis-therapy", "source_name": "Benzinga", "published_at": "2026-06-22T17:15:41", "published_display": "22 Jun 2026 17:15", "sentiment": "positive", "sentiment_pct": 90, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie and Merck Face-Off: Which Pharma Stock Has the Lead?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxQa1ZpblJqX2RGVXc1N3UwZUxiZ041RDBqbUR2Q04xaUR1WXJmWVJIdmFmdnVkUUkyV0ZWamdORlgwUmJSMHU0d2JJUXpYWEZIemxOY1o3TlV4YmpOcjdjYTh1X0dVejVIZzdqZzZkR3dfZ1ZXdWN1U0hXQXVpU3B6R2M0X2t6eUU4R2NFLTR3Q2R1ay1XY1VlNVhZZkNCNUd2QWlXVXlwemE2RjJsREg1LTFvZTZQMWhmZjlRRjhIYkdYNFQ1SlNreXN1TjNTQVJZYmdRRTYzVFA?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-06-22T15:17:59+00:00", "published_display": "22 Jun 2026 15:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck Stock\u2019s New Drugs Were Already Answering The Big Question", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNZ01nZDVVR3VtUXdvTWt6RVltR1dLYXM3TXZIWjlCaHBUS2N3RWpJMjFNNVZsWFFlMFFWWTh6cWExcWdZM0VxcVZ1ZlpXaHJrVGhjcHJnRWlXNHRRY3kyM0hQbV9IMF85Vl9VZEpHS1lhMVpjSFY1WVFDeUpOQ014VkhBU0stTFFkeG1hRVJYSm0yMjJibTR2TEVwbFo2dl9yeFE2M2FQdHBud1RhaUhqVTNNNUhYZVQ0UkItRlFxOA?oc=5", "source_name": "Trefis", "published_at": "2026-06-22T14:45:53+00:00", "published_display": "22 Jun 2026 14:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck\u2019s Oncology Engine Is Still Accelerating (NYSE:MRK)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxPelUxekdCSFJtMVBXanAyektSMndtVlVpYnB4SmtTajY0OTh6NWwtWmFSX2o2VVhCbXhVZEpQdUFadDNXenc5bE4yd3NBQnZUb0FBdF83Tnc5TENBZF9CUU4xdWo5azdCazlhX3ZPVUpzZEtsTlBrdS1fX01PQWg4SGEwMmZLcllW?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-22T14:33:59+00:00", "published_display": "22 Jun 2026 14:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck (MRK) Reports Promising Phase 3 Study Results for Tulisoki", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOTVdid3pGSUVTYWNra2N6SzVuLXBWUG85em81SVlrLUc4RFE1T2NFamVWTDdwNlllTW1mc1JweV9VaDZuYndzVVE5S19vaTgtbmVOS0VOdWFFQVFtcEphd0U5elRzLUYxZGJ0Yklrc0JBTnl0dWJQNDllNlJseXZzSHFiZFZIVkd6ME1JeVBpY3JHSWlVZVo3a0t6Q1VjajZSbGJraFRjc20?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-22T11:35:10+00:00", "published_display": "22 Jun 2026 11:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sanofi swaps R&D leaders; Merck\u2019s Prometheus deal pays dividends", "summary": "", "url": "https://finance.yahoo.com/m/96cd8c91-4307-3140-a31a-96be78239b82/sanofi-swaps-r%26d-leaders%3B.html", "source_name": "BioPharma Dive", "published_at": "2026-06-22T11:12:00+00:00", "published_display": "22 Jun 2026 11:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck (MRK) Wins FDA Expansions, Posts HIV Data, And Ends Lung Cancer Trial", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/merck-mrk-wins-fda-expansions-111003871.html", "source_name": "Simply Wall St.", "published_at": "2026-06-22T11:10:03+00:00", "published_display": "22 Jun 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Berenberg Adjusts Price Target on Merck & Co. to $125 From $115, Maintains Hold Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/berenberg-adjusts-price-target-merck-102310569.html", "source_name": "MT Newswires", "published_at": "2026-06-22T10:23:10+00:00", "published_display": "22 Jun 2026 10:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck\u2019s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)", "summary": "Merck announced positive topline results from its Phase 3 ATLAS-UC induction-only study for tulisokibart (MK-7240), an investigational anti-TL1A monoclonal antibody, in patients with moderately to severely active ulcerative colitis. The study successfully met its primary endpoint", "url": "https://www.businesswire.com/news/home/20260622057174/en/Mercks-Tulisokibart-Met-Primary-and-Key-Secondary-Endpoints-in-the-Phase-3-ATLAS-UC-Induction-only-Study-in-Patients-With-Moderately-to-Severely-Active-Ulcerative-Colitis-UC", "source_name": "Business Wire", "published_at": "2026-06-22T10:45:16", "published_display": "22 Jun 2026 10:45", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Merck (MRK) Is Using KEYTRUDA and WELIREG to Deepen Its Kidney Cancer Franchise", "summary": "Merck (NYSE:MRK) is strengthening its kidney cancer treatment portfolio with the FDA approval of KEYTRUDA and an easier-to-administer version, KEYTRUDA QLEX, when used with WELIREG for certain post-surgery kidney cancer patients. This approval expands the utility of KEYTRUDA, Mer", "url": "https://www.insidermonkey.com/blog/why-merck-mrk-is-using-keytruda-and-welireg-to-deepen-its-kidney-cancer-franchise-1786462/", "source_name": "Insider Monkey", "published_at": "2026-06-22T07:58:26", "published_display": "22 Jun 2026 07:58", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck & Co. Stock - long-term cancer franchise and pipeline in focus", "summary": "This article examines Merck & Co.'s long-term growth strategy, emphasizing its reliance on the blockbuster cancer drug Keytruda and a robust late-stage pipeline. It details the company's business model, revenue streams from oncology and other therapeutic areas like vaccines and a", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/merck-and-co-stock-long-term-cancer-franchise-and-pipeline-in-focus/69591930", "source_name": "AD HOC NEWS", "published_at": "2026-06-20T16:40:28", "published_display": "20 Jun 2026 16:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck & Co. Stock - Long-term growth story and business model on Saturday review", "summary": "This article examines Merck & Co.'s long-term growth story and business model, highlighting its strong oncology and vaccines platform. Key revenue drivers like Keytruda and Gardasil are discussed, along with analyst sentiment and the company's financial standing. The report provi", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/merck-and-co-stock-long-term-growth-story-and-business-model-on/69589935", "source_name": "AD HOC NEWS", "published_at": "2026-06-20T12:08:10", "published_display": "20 Jun 2026 12:08", "sentiment": "positive", "sentiment_pct": 69, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck & Co., Inc. Sued for Securities Law Violations - Investors", "summary": "Levi & Korsinsky LLP has filed a class action securities lawsuit against Merck & Co., Inc. (NYSE: MRK) on behalf of investors who suffered losses due to alleged securities fraud between February 3, 2022, and February 3, 2025. The lawsuit claims that Merck misled investors about i", "url": "https://natlawreview.com/press-releases/merck-co-inc-sued-securities-law-violations-investors-should-contact-levi-0", "source_name": "The National Law Review", "published_at": "2026-06-19T02:10:29", "published_display": "19 Jun 2026 02:10", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CPI-232419 Archives", "summary": "Merck has completed its $10.8 billion acquisition of Prometheus Biosciences, making Prometheus a wholly-owned subsidiary. This acquisition positions Merck to pursue an immunology blockbuster, with Prometheus's lead candidate currently being tested for ulcerative colitis and Crohn", "url": "https://www.pymnts.com/cpi_tag/cpi-232419/", "source_name": "PYMNTS.com", "published_at": "2026-06-19T01:10:20", "published_display": "19 Jun 2026 01:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck (MRK) Stock Falls Amid Market Uptick: What Investors Need to Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPeHhfSG9DWG5nXzRXdGh4Q0VFVVg4aFZBV2Z6a2RHTU1EZ0JSWjdxel9xSW5GRElrMkgtbDFzTFV0SGhobXZxTFlJcGluaW5NaGM2MUFraTl0Y1ZZcGZPVG5hUkMyczEwOWFhNFUxQXdYQk1Mc01ETlBmZkFSdnBwYjB0c1NBYmlfWWVtcTgwN1lsd2xFUkE?oc=5", "source_name": "Market source", "published_at": "2026-06-18T21:50:04+00:00", "published_display": "18 Jun 2026 21:50", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck & Co. Stock - Analyst consensus and valuation snapshot", "summary": "This article provides a snapshot of Merck & Co. stock, detailing its current trading data, analyst consensus, and key valuation metrics. It highlights the company's strong position in the large-cap pharma sector, driven by its oncology, vaccines, and cardiometabolic franchises, w", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/merck-and-co-stock-analyst-consensus-and-valuation-snapshot/69575619", "source_name": "AD HOC NEWS", "published_at": "2026-06-18T18:38:13", "published_display": "18 Jun 2026 18:38", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck & Co. Inc. stock outperforms competitors despite losses on the day", "summary": "Shares of Merck & Co. Inc. (MRK) decreased by 1.36% to $113.87 on Thursday, despite an overall positive trading session for the stock market where the S&P 500 Index and Dow Jones Industrial Average both saw gains. This downturn ended a two-day winning streak for the company's sto", "url": "https://www.marketwatch.com/data-news/merck-co-inc-stock-outperforms-competitors-despite-losses-on-the-day-27f0f94c-02bcf21041f3?mod=mw_quote_news", "source_name": "MarketWatch", "published_at": "2026-06-18T16:34:00", "published_display": "18 Jun 2026 16:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Expands Merck Pneumococcal Shot Label To Include At-Risk Children And Teens", "summary": "The FDA has expanded the label for Merck's Capvaxive pneumococcal shot to include at-risk children and adolescents aged 2-17 with chronic conditions, making it the only vaccine specifically studied and indicated for this group in the U.S. This decision was based on Phase 3 STRIDE", "url": "https://www.benzinga.com/news/fda/26/06/53281318/fda-expands-merck-pneumococcal-shot-label-to-include-at-risk-children-and-teens", "source_name": "Benzinga", "published_at": "2026-06-18T15:29:07", "published_display": "18 Jun 2026 15:29", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck wins U.S. label expansion for pneumococcal shot (MRK:NYSE)", "summary": "Merck announced that the U.S. FDA has approved a label expansion for its pneumococcal vaccine, Capvaxive. The expanded indication now includes immunization for children against Streptococcus pneumoniae. This approval widens the potential patient population for Merck's vaccine.", "url": "https://seekingalpha.com/news/4604778-merck-wins-us-label-expansion-pneumococcal-shot", "source_name": "Seeking Alpha", "published_at": "2026-06-18T12:23:03", "published_display": "18 Jun 2026 12:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA expands Merck\u2019s CAPVAXIVE for children at pneumococcal risk", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPYWM0ZVFrel9TcktfbVRPME92UG9aY1VyNDlteHFQak9peHdsN0ZFODNEeklrRWhzTnJBWUNDQzJpTy1GaWlMYk96THM4Y3U2VHNwc0ZWNS1JakNIN3RGYUlyWGRUNkh4MkZPXzdwTXhsbDlsU2lpbGFZVmVjeGxFQTdqLWlDOF9HRm9YNFVwVnZWWUtzYXRyTnZnMTR3RlgzUzdjdWNWSm5iTmJOMXJXODFtRjZjWjB3bFNTWUl0WQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T10:45:00+00:00", "published_display": "18 Jun 2026 10:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alignment Healthcare And 2 Other Stocks That May Be Trading Below Estimated Value", "summary": "This article highlights three US stocks\u2014Alignment Healthcare (ALHC), Ouster (OUST), and Tutor Perini (TPC)\u2014that are identified as potentially undervalued based on cash flow analysis. It provides an overview of each company, their estimated discount to fair value, revenue and earn", "url": "https://simplywall.st/stocks/us/capital-goods/nyse-tpc/tutor-perini/news/alignment-healthcare-and-2-other-stocks-that-may-be-trading/amp", "source_name": "Simply Wall Street", "published_at": "2026-06-18T11:39:15", "published_display": "18 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "sector", "tier_label": "Sector context"}, {"title": "Merck's pneumococcal vaccine wins US approval for high-risk children, teens", "summary": "Merck's Capvaxive pneumococcal vaccine has received expanded approval from U.S. health regulators for children and teenagers aged 2 to 17 who are at a higher risk of bacterial disease due to chronic health conditions. This vaccine protects against multiple strains of Streptococcu", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/mercks-pneumococcal-vaccine-wins-us-approval-high-risk-children-teens-2026-06-18/", "source_name": "Reuters", "published_at": "2026-06-18T10:45:00", "published_display": "18 Jun 2026 10:45", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here\u2019s Why Merck (MRK) is Among the 10 Undervalued Counter Cyclical Stocks to Buy Now", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxQV29KWTduWHJyWHJ3NkxCRmFBc2swdmg2UUdqZ3RTcF9nZjZuSktHYWFCWnJLQURWUVozVHlJdlRZaklSaWZHdWxTaEozWVo0azg3bjJId1VDWEFzZXljdHRQd1lTSm4yekRJSTZZeXFNSjREVFpFWldLM043YTJpWTI2VVl6SmFPbW5Z?oc=5", "source_name": "Market source", "published_at": "2026-06-17T17:35:12+00:00", "published_display": "17 Jun 2026 17:35", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck & Co. Inc. Stock (US58933Y1055): Quarterly earnings and Dow Jones role in focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQWDlQNGdVbzM2SlZ1RVZ6cFdkWEpPS3FuLVRQeFgzdnB6aUdyendwcW5aWENMdmh3VmktX1BtN19rSGlyQm1mcmFCNlk1QUNHVGlIY01UcVR6NnMtUUVobDMwQU8zeHFkbTZzUVd5SFkwR0Z2X2lpc01OZTcwUVdJRG5KWkFaMFBjeWpXYVZ5aDNtdklrUmhDUmozS1lfb0hHWEVuRnR0aWdxcUhSRWlUSUlacHdRNF9WT1VEdnZR?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-06-16T18:04:48+00:00", "published_display": "16 Jun 2026 18:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck & Co., Inc. Stock (US58933Y1055): Dow component under pressure after 3 percent slide", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPazBNRk5yZHJlOFpGeWxQU00zdHRSYTBTdHp3NW9PdklJek1qYlVyWU82T0JaSkkwMmdaTmluRWYzaDJfTGdKaEx4dUhUZmFoR3RtRzRjM2t5VS11OVpRLTY2dDlTNFdmUVlHSl9vbU5TLU5PWWdmemhjeTBTcWcwN1I5SXZPdktQYjFFNmp1eWw1UjEweTliUHBybWM1N05QT3g5ejFPWmpaeTBPeUw4S01TS2xxXzg1VFpiZzg2YzQ?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-06-16T15:30:09+00:00", "published_display": "16 Jun 2026 15:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck & Co. Inc. Stock (US58933Y1055): Valuation and fundamentals in focus after steady trading", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPU0EzMGdscUlvREhYNDBkbVF6S1kyVHA0dmJ1YW1ONFgyanZOSVNZc3VBY2RwQUtzR2tUN2Q4Y0k4SWxvc0ZIeXFEZHVkczRUZ3pTSGx4eUJuMG5FZi1IZEZmV1pXVE81S3lPVWNEY29QRlFGcHNCYTYzVmM0MWJYSHdKMkU3dVRCQjhET05waHNSdW41R1FtUE81MU1jdTJOM3dKeDNGNW5CXzBjNmFTVGdSMXRrajdnYnA0R2tWSzZlUQ?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-06-14T18:50:51+00:00", "published_display": "14 Jun 2026 18:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck (MRK) Stock After 53% One-Year Gain Is DCF Signaling Further Upside Potential", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxNSDlaTkQxdkN4NFl0YjZWeDhlVG01OERwcll1QThOVTA5c2UzNGs1Tl9oVDNyWGxyc2NWSTQ5OFk3NU5NTGxrUjNWWG5rekJ4dGo4WGNCN3VGLVZGeXBLdnltVXc0VFZoVzlXWTdncmNPdFUwWXpjWWFTYl9BNE93RERESHdXMkdTTWZnU3lSOFU?oc=5", "source_name": "Market source", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck & Co., Inc. Stock (US58933Y1055): Dow Jones Component Moves Higher In Thursday Trading", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQd1dmLWNTdEhiSHlxUU5kSWhaNEh5cUZrYlRDbmJxQ2ZLTWdvX084czhFVlZfVHEyUl9pUS1JOFB3a3VSWFRYZ2pvbWcwemk4NU55U0VvMXJxWU9TX2lqWk9jbFpHek9uMWctbG42MnBHS1pkdTlfSGtLZVVHYzJqMkVEa2Q3XzN3UU15LWhTclFEZ2NrcDdTa2s4eHVQWVNOcU04LU8zM0Y3WjBwY2ZBRmYwZm90QU80VVAxeg?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-06-11T17:44:04+00:00", "published_display": "11 Jun 2026 17:44", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck & Co., Inc. stock (US58933Y1055): Cancer portfolio drives growth amid patent and pricing quest", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxQOVR1SWltczJjTWt4NG81LTZrWmZGbUJLMmxGNk1tYkZ6T1RlMGo1SjdZNDktMU1pNDUwWVNmOWlYZkkyWUdudFE2ZzRYMldEcWQwWDNMdXo5MzdrVWMzRERaQlMtZFJDUFNTZW5PYVZCYnJ6MFFwazlSX0pEX1RCQ282a05mOWdmTmZVRTAyeXRiNnEtRWRpN2xEOTdybGhwRnNwV1ZfVU5PMFpDcDFpelk4ZDY4aklKX1VNVVJUYUQtQmc?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck & Co. stock (US58933Y1055): What investors are watching now", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNcDFaSmpiX2ppcFltMjdNYmlTY3hKZ05XUzltVldfWURiUk9PWkQ2ekZ1cmw3Z2ZpNzc1TUFJRV9tM1JvSDFqUjZwTWVrU251VFg2SXJkRnlZdXowby1iZnpLLW4wNDFFT0lwRVZ0WU5Tbk9qaU9lNWg5aUZtOHpnUjNNVGNOOXAxby1XVmhGTE1HSnE3V1FIbDhGUHBZNnNIQkNXcHNsQm5oR1I3OFBsNGJpX09Bb2JJZk1oWTJUSQ?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck & Co.: Why The Market Is Right To Start Buying Into Post-Keytruda Promise (NYSE:MRK)", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPdVNnNWNEV1N0X1N6YXJTT0w2SHNXcE1YZTZjbmRDV2RMd1hreG1jaGh3OXFZakplZ3RWY2JxcG1PbGNXQVcySWJ2V1dPRUZLUnpzSGMzcGdNNTlKRlJSWEMzZG1zM2tEdE1BVmVJeXpNOWtzSzVWV3VDTmNSTy1CSV9qRXZqUFozNGdiU3RTd1BiN1NzUXcyYjEzaHl0WWJ1cVV3QS1ydU9UUVF5cm9qejRMaUtLbUtsT284UQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Meet the Biotech Stock That's Trouncing Lilly, Merck, and Pfizer in 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQRzRaYk5Fa2YzREt0VGdGaDdMRExVX1BqUmtZSjROZkFhRktZMUNFb2xiRWRDWHNWSS1hWlRtajg2NS1MekpoZ0NPekVMWjhWd3ZLRlNwa1M1VWpubXpRWWV4Z0JFWDN5ZVlBTnhGZkFPd2J2YVlzUjg0dUd2MF9zNTlhV3lJMjVDbjdkWGQwaW1yR1gtQlpPYw?oc=5", "source_name": "The Motley Fool", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck & Co., Inc. stock (US58933Y1055): shares steady on NYSE as investors digest recent news flow", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQSk93QUpaVHplbi1CLTBVM25FUEE2U1BXUEhmdEpRQ2M3UVNMN04tTmMzaFZ3ZjVtVThTZFpsRzlqYkwtQkxoMUVWaHFwVlRWWi0wTy10WkstRTdFeElDMEhFSEZwdHRaUmIyWFJUQVpCWjFIMzFkSVhkTVFWWTVMX1BjLUx4WlUyY1l3djdZRlRSd0M3WTcyUjhhQzJaNmxuV2FhMHV0ZWVRVy1URE16emFzM0RKc0NaUXJz?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck Stock After a 60% Rally From Its Lows: Is It Still Worth Buying at $120?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPblVJMXc5SFdGYlZwZkNEdUl5RlIxTzlqYnFib0tKXzU0UmFxd1h1cEk0VUtJaWI1b2pzRlNUTVZDNlhtNlFReVFBUHpyemFYYmZQM1BuV2ZvVFpqakJsejd5TGhSSW9ncG0xWWRnemtIWmVVOHFqN1RzSzBIWktRSDl0b3J1akxaRFdDX2s3LWVHdTBKY1JDYU5lQk1PWDI0U2c?oc=5", "source_name": "TIKR.com", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Five-Year Tally: Merck Stock Delivers $47 Bil Gain", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQQUdPUjZtLV9rWVowSHhQQTlCQ3dTWXE1NmRMMERBazVka2hmTDJkODhNUDQ3dkhCVm1vZDZnelVjN2tGeDIwdUs2RzJWZ1loMng4ZWJfUXFfUXhuZnRDQXJXVXZla1UyWXBScjJvVk5CZnJidXFiYXBhQjhvb1Nmd25vZ3lsTVNWN0hmVEJaU0t6emFKTDNrODZPU2RjOVRUb19lRndkZ3UyZTJr?oc=5", "source_name": "Trefis", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck & Co. stock (US58933Y1055): A major patent update and product pipeline remain in focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQUUJJVkRjWERFV3laSFp2elRKTGQ4T0hXMGJuYmxCWlFvemlaNnJuamtZRlBEVVJIYWlMZ1FvVDdVZTQyZXRZbUJwRnotdk1oUUtXUUpTTnNjSDlyS0NUdzNONHJkTkFFVy1sT2xQbUJLWkdvNDhvNkRUdVlEd1QwSC1mWlUxMHN6R2Z6M1lsUm9zM3dmRzB2M2JRVWV6VTN3ekktTmlVU0hHTG1FUTlodFVQR1RsRVg1QUtrRm1MRWJydw?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck Stock Zooms Closer To A Breakout On 'A New Chapter' In Cancer", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOcFQ4QWZTdEF3QzFxYVZwTllCbElES2xTeXFzTWdpN1B5RVdpMmJPSVFfeWhIR3RoUUlkenUtMGtLcnFaak1XcFlaX3pRakJWZC1YOTFvWncwcGk4STZhVlFhcmE2SkJUOGRNUXRkTUp0akJUcjlBRUdLb3BDVzhHX0d0YTZ5WklJNlNyQmxURk40SDZLUDNqZXAtTUEyM0FKb1VfNldzdkU1b0pm?oc=5", "source_name": "Investor's Business Daily", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck Completes Acquisition of Terns Pharmaceuticals, Inc.", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNSTZWTWdvaHp2Zk16aFZ2TGdGUnBBZHR0TG0xbW1XckRma05aWmFkVFpFTFd5OFU3Tlh3U0JKMXV0Wk9SUlVacWptYUVnVXJ0RFViRnEtcENSdzRCcURmRUFiRURHTEs2NlQtVTFMRjNscmkyeVdaM2R3WGM0SkhJaFFnaUptaDg5VWZTMjJ1VXU0UVRzeUJQRGVVX1d2SDNDTnc5ZWQtaXBYNlZQaGZtdUFiVUQ?oc=5", "source_name": "Business Wire", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck Rises 11% YTD: Should Investors Buy, Sell or Hold the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPX202QklDZXVScVlBQ2w1ZVRVTk9uNVFPcXVkU2Z5VzRpWmxJT044aFpvMGdWS201Ul91TXRKM1NXS1JhTWIzV1A5LVNuSUFoaklEOVdlTWJ2R29WaDhoSDlnNkJMSHJpYWhWVjdaQmMxWWowemRaLXhzaGp0UjVyU0Z2QlFCSU5lb0E0SEt3QXRwVmphUV9FLVBWR1JWd1VaSzA0b09MOUpScjNxMWN6eDdTVlhUSVpiekE?oc=5", "source_name": "TradingView", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Merck (MRK) Shares Are Trading Lower Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOa2dWeTZvblFOdXpGRk0wUXhzQ2pIWU05dkYzQTY5em1ab2hsemRxRm1nb1lWdE9FbmJ5bUNHTTVDc2phdXZHTnFsanBiSUlxZTBBd1c3QmhiNzRRcEVacEduUENSS1c0OUtzcmtPX0huTHU3SXR6UVVyS2VvV0d4eFhvTmdvVlFnbUhCWmt2bUJYWXBZdW9kczlTbXFFUQ?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck (MRK) Stock Sinks As Market Gains: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxOZG9JMVV6ZkFFWm9lZTllT184YVFYTWVMNkNyQXhjRWt2dWIxWXQ4NDcyNmktaHhyX0dLRWhtRHBFaHA0bzNTVDllQ0l4eGdKcEtpSGFhVV9QLUV6LTVPemt6Tm9YVGJySkZSQ3F4enVLbGVBRW96ZUxGUXNoMURqZU12c0pSb1Z1cGJlWVNBbkU3RUhqNHdDVg?oc=5", "source_name": "Market source", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck (MRK) Stock Declines While Market Improves: Some Information for Investors", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNZ3htU2ZvamV2MUtPNWRxbk1KbGl1Z3ZNclkxQlJTZzd6RzdhaUFKNGdnU3JqRFFScllMLU5Gb3YxNkVWLUw5X0xCS3hGR0FkNGdtc1ZfSUxKZTU2NXNMODNXbjNtY05icFBhSFVKUmRnMjdYVER1YUZLYXNsOU5qU2ZZZVZOa01nc1FZTzM2bk0zNnFucnM1cE1Zdw?oc=5", "source_name": "Market source", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck CFO and R&D chief join TD Cowen health care fireside chat", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOcHRreDJJbDA3VUdkWDd6a3V5U2FUZkMyV2ZaeTUxOTN3bXNQUVkxSmNJWVRZNlhoeE82WlpNVmp1dnBneXN1dlpSakNndDliR05uSTdGWXBYdjBHaHlYR0FHYXBBVlVLMURQZWRlbWNVaHNRdEdSX2VwMVRwbEp5dDNPdUt5MVlCY0w2UjIxZ3BoQ3hVdGhtRVFDOEpyLU9jd1dBaGZBV3NnckdSMFFVMm9oN3c?oc=5", "source_name": "Stock Titan", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck & Company Stock Forecast 2026\u20132030 | Future Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMifkFVX3lxTE5MWktOSWJuTjNTbU1EZWVEUHlJeUdBNWc3ak9TN0RIMTFCQVRNZmpZdTRDMXl6aHhobXNoTTc0a0VNWGlhdno3RVlCVzdKazdmV3hxV1l3WTN4Tm9MeDQyY0UwbjJOWUtBUXdKbWtrSFBBZXdMSEF6UmNlQ3pBZw?oc=5", "source_name": "Capital.com", "published_at": "2026-02-18T08:00:00+00:00", "published_display": "18 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck Stock (MRK) Hitting Highs Into Earnings \u2013 Eyes On Breakout", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPU01ZWHVVLW9nUHQ3RDFuWmZrT3dmZ3VaNG1jWUNWanh6eGhlaWxmbkZ2X0JHX2NlZEg0ZEtsTHo4WTk0Ymc2Qm9CTml1U1dyNVdraFV5LXlPcGh1bDhZOFhILUZDdk9lVGNWdXpiY1FZODQtMFpGLTgzd2RFODlpRy1RU3FvdkJHWXVqRTRkUHo4NFNjVklSdnZ6dnNTUQ?oc=5", "source_name": "AskTraders", "published_at": "2026-02-03T08:00:00+00:00", "published_display": "03 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck to Complete Acquisition of Cidara Therapeutics", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNd0pqd3JNOVJxaDB2eUVZazhhZmJwc3REbGRZNUVrTGxqMFJIcFJJV0pzYlM5ODdQSUZiRnFOajRpeXRxS2lYWUJmNFIwLXkxN2hIMjhma0FwZjhhdzBVdlZ1R0RPYkpna2VXLTVDSVB0cmlXRW03Vk52ZTdlZlVMVGFkTTRYU2N3M0I5TnlaNGhKYllBLVBTSFFWWGxJUlJaUXM3X3VvUmNlaWsydEE?oc=5", "source_name": "Business Wire", "published_at": "2026-01-07T08:00:00+00:00", "published_display": "07 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here Are Thursday\u2019s Top Wall Street Analyst Research Calls: Digital Realty, GE Vernova, Micron Technology, Merck & Co., Rivian, United Airlines, and More", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAJBVV95cUxPS1AxVUZ2LU9jaURHWTNZM1ExTVVsQ3lmclhrQUFRSy15ckl2M3dhb0NPX05ZMVpJMzBnZVBCQXV6c041bERpcEI1SmlJVVpaMWNicjRDRkM5dl9NV3dHTWlCdTVrNzNyREo0OHpIQ3FjelBmYWdqNmtkM2d4ZktKYmNuTUhCNW1JSjByTkxfSFZ6bTdEanlMbDc1T3pJZGdncENuN3NfY1QzTlF5eGFucXdOOUtac3RMZjkzRFlWczB3b0lra0tRMEVQTlEwS0pwYnNWMlU2Z0QtMjk5TTlnNml6ZWtoeHFfNzlhUWxIVmx3Mmkwa25WNDZ4ckptMFQybkFVdWFSTXhPQjZOY2tkNjB3Mko?oc=5", "source_name": "24/7 Wall St.", "published_at": "2025-12-18T08:00:00+00:00", "published_display": "18 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stock of the Week - Merck & Co Inc (23.10.2025)", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQN2FBUlJkQ1F2dWJXRURMWmlONDlzZDg5bUZudC1SZFlJdzhBLVRiOHREcnZ6Q1JQQ1JZb1plUW5UNGJjQWpKYTNiTDVuREJpRENuLTZxWG15RkhJLURzZktJX3lpRUdvWDV1OVFaaERIZGdGaFp5eHRxMWlHM2tlUm1kRENFUGE3NC1RZjhRUVRLMnFlb1NOQkdzd2d3dWNG?oc=5", "source_name": "XTB.com", "published_at": "2025-10-23T07:00:00+00:00", "published_display": "23 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Merck Expands TL1A Lead With Positive Tulisokibart Results In UC", "summary": "Merck has announced positive results for its drug Tulisokibart in ulcerative colitis trials, further strengthening its leadership in the TL1A drug class. This development highlights Merck's expanding pipeline in immunology and potentially impacts future treatment strategies for i", "url": "https://insights.citeline.com/scrip/r-and-d/clinical-trials/merck-expands-tl1a-lead-with-positive-tulisokibart-results-in-uc-6G3T6ZR4KFDPZPCM4FAAWNQWVY/", "source_name": "Citeline News & Insights", "published_at": "2026-06-22T19:30:19", "published_display": "22 Jun 2026 19:30", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck Scores Key Phase 3 Win For Novel Ulcerative Colitis Therapy", "summary": "Merck & Co. announced positive results from its Phase 3 ATLAS-UC induction study for tulisokibart, a novel anti-TL1A therapy for ulcerative colitis. The drug met its primary endpoint of clinical remission at week 12 and key secondary endpoints, with a safety profile consistent wi", "url": "https://www.benzinga.com/news/health-care/26/06/60024141/merck-scores-key-phase-3-win-for-novel-ulcerative-colitis-therapy", "source_name": "Benzinga", "published_at": "2026-06-22T17:15:41", "published_display": "22 Jun 2026 17:15", "sentiment": "positive", "sentiment_pct": 90, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie and Merck Face-Off: Which Pharma Stock Has the Lead?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxQa1ZpblJqX2RGVXc1N3UwZUxiZ041RDBqbUR2Q04xaUR1WXJmWVJIdmFmdnVkUUkyV0ZWamdORlgwUmJSMHU0d2JJUXpYWEZIemxOY1o3TlV4YmpOcjdjYTh1X0dVejVIZzdqZzZkR3dfZ1ZXdWN1U0hXQXVpU3B6R2M0X2t6eUU4R2NFLTR3Q2R1ay1XY1VlNVhZZkNCNUd2QWlXVXlwemE2RjJsREg1LTFvZTZQMWhmZjlRRjhIYkdYNFQ1SlNreXN1TjNTQVJZYmdRRTYzVFA?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-06-22T15:17:59+00:00", "published_display": "22 Jun 2026 15:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck Stock\u2019s New Drugs Were Already Answering The Big Question", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNZ01nZDVVR3VtUXdvTWt6RVltR1dLYXM3TXZIWjlCaHBUS2N3RWpJMjFNNVZsWFFlMFFWWTh6cWExcWdZM0VxcVZ1ZlpXaHJrVGhjcHJnRWlXNHRRY3kyM0hQbV9IMF85Vl9VZEpHS1lhMVpjSFY1WVFDeUpOQ014VkhBU0stTFFkeG1hRVJYSm0yMjJibTR2TEVwbFo2dl9yeFE2M2FQdHBud1RhaUhqVTNNNUhYZVQ0UkItRlFxOA?oc=5", "source_name": "Trefis", "published_at": "2026-06-22T14:45:53+00:00", "published_display": "22 Jun 2026 14:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck\u2019s Oncology Engine Is Still Accelerating (NYSE:MRK)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxPelUxekdCSFJtMVBXanAyektSMndtVlVpYnB4SmtTajY0OTh6NWwtWmFSX2o2VVhCbXhVZEpQdUFadDNXenc5bE4yd3NBQnZUb0FBdF83Tnc5TENBZF9CUU4xdWo5azdCazlhX3ZPVUpzZEtsTlBrdS1fX01PQWg4SGEwMmZLcllW?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-22T14:33:59+00:00", "published_display": "22 Jun 2026 14:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck (MRK) Reports Promising Phase 3 Study Results for Tulisoki", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOTVdid3pGSUVTYWNra2N6SzVuLXBWUG85em81SVlrLUc4RFE1T2NFamVWTDdwNlllTW1mc1JweV9VaDZuYndzVVE5S19vaTgtbmVOS0VOdWFFQVFtcEphd0U5elRzLUYxZGJ0Yklrc0JBTnl0dWJQNDllNlJseXZzSHFiZFZIVkd6ME1JeVBpY3JHSWlVZVo3a0t6Q1VjajZSbGJraFRjc20?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-22T11:35:10+00:00", "published_display": "22 Jun 2026 11:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sanofi swaps R&D leaders; Merck\u2019s Prometheus deal pays dividends", "summary": "", "url": "https://finance.yahoo.com/m/96cd8c91-4307-3140-a31a-96be78239b82/sanofi-swaps-r%26d-leaders%3B.html", "source_name": "BioPharma Dive", "published_at": "2026-06-22T11:12:00+00:00", "published_display": "22 Jun 2026 11:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck (MRK) Wins FDA Expansions, Posts HIV Data, And Ends Lung Cancer Trial", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/merck-mrk-wins-fda-expansions-111003871.html", "source_name": "Simply Wall St.", "published_at": "2026-06-22T11:10:03+00:00", "published_display": "22 Jun 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Berenberg Adjusts Price Target on Merck & Co. to $125 From $115, Maintains Hold Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/berenberg-adjusts-price-target-merck-102310569.html", "source_name": "MT Newswires", "published_at": "2026-06-22T10:23:10+00:00", "published_display": "22 Jun 2026 10:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck\u2019s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)", "summary": "Merck announced positive topline results from its Phase 3 ATLAS-UC induction-only study for tulisokibart (MK-7240), an investigational anti-TL1A monoclonal antibody, in patients with moderately to severely active ulcerative colitis. The study successfully met its primary endpoint", "url": "https://www.businesswire.com/news/home/20260622057174/en/Mercks-Tulisokibart-Met-Primary-and-Key-Secondary-Endpoints-in-the-Phase-3-ATLAS-UC-Induction-only-Study-in-Patients-With-Moderately-to-Severely-Active-Ulcerative-Colitis-UC", "source_name": "Business Wire", "published_at": "2026-06-22T10:45:16", "published_display": "22 Jun 2026 10:45", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Merck (MRK) Is Using KEYTRUDA and WELIREG to Deepen Its Kidney Cancer Franchise", "summary": "Merck (NYSE:MRK) is strengthening its kidney cancer treatment portfolio with the FDA approval of KEYTRUDA and an easier-to-administer version, KEYTRUDA QLEX, when used with WELIREG for certain post-surgery kidney cancer patients. This approval expands the utility of KEYTRUDA, Mer", "url": "https://www.insidermonkey.com/blog/why-merck-mrk-is-using-keytruda-and-welireg-to-deepen-its-kidney-cancer-franchise-1786462/", "source_name": "Insider Monkey", "published_at": "2026-06-22T07:58:26", "published_display": "22 Jun 2026 07:58", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck & Co. Stock - long-term cancer franchise and pipeline in focus", "summary": "This article examines Merck & Co.'s long-term growth strategy, emphasizing its reliance on the blockbuster cancer drug Keytruda and a robust late-stage pipeline. It details the company's business model, revenue streams from oncology and other therapeutic areas like vaccines and a", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/merck-and-co-stock-long-term-cancer-franchise-and-pipeline-in-focus/69591930", "source_name": "AD HOC NEWS", "published_at": "2026-06-20T16:40:28", "published_display": "20 Jun 2026 16:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck & Co. Stock - Long-term growth story and business model on Saturday review", "summary": "This article examines Merck & Co.'s long-term growth story and business model, highlighting its strong oncology and vaccines platform. Key revenue drivers like Keytruda and Gardasil are discussed, along with analyst sentiment and the company's financial standing. The report provi", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/merck-and-co-stock-long-term-growth-story-and-business-model-on/69589935", "source_name": "AD HOC NEWS", "published_at": "2026-06-20T12:08:10", "published_display": "20 Jun 2026 12:08", "sentiment": "positive", "sentiment_pct": 69, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck & Co., Inc. Sued for Securities Law Violations - Investors", "summary": "Levi & Korsinsky LLP has filed a class action securities lawsuit against Merck & Co., Inc. (NYSE: MRK) on behalf of investors who suffered losses due to alleged securities fraud between February 3, 2022, and February 3, 2025. The lawsuit claims that Merck misled investors about i", "url": "https://natlawreview.com/press-releases/merck-co-inc-sued-securities-law-violations-investors-should-contact-levi-0", "source_name": "The National Law Review", "published_at": "2026-06-19T02:10:29", "published_display": "19 Jun 2026 02:10", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CPI-232419 Archives", "summary": "Merck has completed its $10.8 billion acquisition of Prometheus Biosciences, making Prometheus a wholly-owned subsidiary. This acquisition positions Merck to pursue an immunology blockbuster, with Prometheus's lead candidate currently being tested for ulcerative colitis and Crohn", "url": "https://www.pymnts.com/cpi_tag/cpi-232419/", "source_name": "PYMNTS.com", "published_at": "2026-06-19T01:10:20", "published_display": "19 Jun 2026 01:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck (MRK) Stock Falls Amid Market Uptick: What Investors Need to Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPeHhfSG9DWG5nXzRXdGh4Q0VFVVg4aFZBV2Z6a2RHTU1EZ0JSWjdxel9xSW5GRElrMkgtbDFzTFV0SGhobXZxTFlJcGluaW5NaGM2MUFraTl0Y1ZZcGZPVG5hUkMyczEwOWFhNFUxQXdYQk1Mc01ETlBmZkFSdnBwYjB0c1NBYmlfWWVtcTgwN1lsd2xFUkE?oc=5", "source_name": "Market source", "published_at": "2026-06-18T21:50:04+00:00", "published_display": "18 Jun 2026 21:50", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck & Co. Stock - Analyst consensus and valuation snapshot", "summary": "This article provides a snapshot of Merck & Co. stock, detailing its current trading data, analyst consensus, and key valuation metrics. It highlights the company's strong position in the large-cap pharma sector, driven by its oncology, vaccines, and cardiometabolic franchises, w", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/merck-and-co-stock-analyst-consensus-and-valuation-snapshot/69575619", "source_name": "AD HOC NEWS", "published_at": "2026-06-18T18:38:13", "published_display": "18 Jun 2026 18:38", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck & Co. Inc. stock outperforms competitors despite losses on the day", "summary": "Shares of Merck & Co. Inc. (MRK) decreased by 1.36% to $113.87 on Thursday, despite an overall positive trading session for the stock market where the S&P 500 Index and Dow Jones Industrial Average both saw gains. This downturn ended a two-day winning streak for the company's sto", "url": "https://www.marketwatch.com/data-news/merck-co-inc-stock-outperforms-competitors-despite-losses-on-the-day-27f0f94c-02bcf21041f3?mod=mw_quote_news", "source_name": "MarketWatch", "published_at": "2026-06-18T16:34:00", "published_display": "18 Jun 2026 16:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Expands Merck Pneumococcal Shot Label To Include At-Risk Children And Teens", "summary": "The FDA has expanded the label for Merck's Capvaxive pneumococcal shot to include at-risk children and adolescents aged 2-17 with chronic conditions, making it the only vaccine specifically studied and indicated for this group in the U.S. This decision was based on Phase 3 STRIDE", "url": "https://www.benzinga.com/news/fda/26/06/53281318/fda-expands-merck-pneumococcal-shot-label-to-include-at-risk-children-and-teens", "source_name": "Benzinga", "published_at": "2026-06-18T15:29:07", "published_display": "18 Jun 2026 15:29", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck wins U.S. label expansion for pneumococcal shot (MRK:NYSE)", "summary": "Merck announced that the U.S. FDA has approved a label expansion for its pneumococcal vaccine, Capvaxive. The expanded indication now includes immunization for children against Streptococcus pneumoniae. This approval widens the potential patient population for Merck's vaccine.", "url": "https://seekingalpha.com/news/4604778-merck-wins-us-label-expansion-pneumococcal-shot", "source_name": "Seeking Alpha", "published_at": "2026-06-18T12:23:03", "published_display": "18 Jun 2026 12:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA expands Merck\u2019s CAPVAXIVE for children at pneumococcal risk", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPYWM0ZVFrel9TcktfbVRPME92UG9aY1VyNDlteHFQak9peHdsN0ZFODNEeklrRWhzTnJBWUNDQzJpTy1GaWlMYk96THM4Y3U2VHNwc0ZWNS1JakNIN3RGYUlyWGRUNkh4MkZPXzdwTXhsbDlsU2lpbGFZVmVjeGxFQTdqLWlDOF9HRm9YNFVwVnZWWUtzYXRyTnZnMTR3RlgzUzdjdWNWSm5iTmJOMXJXODFtRjZjWjB3bFNTWUl0WQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T10:45:00+00:00", "published_display": "18 Jun 2026 10:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck's pneumococcal vaccine wins US approval for high-risk children, teens", "summary": "Merck's Capvaxive pneumococcal vaccine has received expanded approval from U.S. health regulators for children and teenagers aged 2 to 17 who are at a higher risk of bacterial disease due to chronic health conditions. This vaccine protects against multiple strains of Streptococcu", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/mercks-pneumococcal-vaccine-wins-us-approval-high-risk-children-teens-2026-06-18/", "source_name": "Reuters", "published_at": "2026-06-18T10:45:00", "published_display": "18 Jun 2026 10:45", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here\u2019s Why Merck (MRK) is Among the 10 Undervalued Counter Cyclical Stocks to Buy Now", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxQV29KWTduWHJyWHJ3NkxCRmFBc2swdmg2UUdqZ3RTcF9nZjZuSktHYWFCWnJLQURWUVozVHlJdlRZaklSaWZHdWxTaEozWVo0azg3bjJId1VDWEFzZXljdHRQd1lTSm4yekRJSTZZeXFNSjREVFpFWldLM043YTJpWTI2VVl6SmFPbW5Z?oc=5", "source_name": "Market source", "published_at": "2026-06-17T17:35:12+00:00", "published_display": "17 Jun 2026 17:35", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck & Co. Inc. Stock (US58933Y1055): Quarterly earnings and Dow Jones role in focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQWDlQNGdVbzM2SlZ1RVZ6cFdkWEpPS3FuLVRQeFgzdnB6aUdyendwcW5aWENMdmh3VmktX1BtN19rSGlyQm1mcmFCNlk1QUNHVGlIY01UcVR6NnMtUUVobDMwQU8zeHFkbTZzUVd5SFkwR0Z2X2lpc01OZTcwUVdJRG5KWkFaMFBjeWpXYVZ5aDNtdklrUmhDUmozS1lfb0hHWEVuRnR0aWdxcUhSRWlUSUlacHdRNF9WT1VEdnZR?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-06-16T18:04:48+00:00", "published_display": "16 Jun 2026 18:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck & Co., Inc. Stock (US58933Y1055): Dow component under pressure after 3 percent slide", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPazBNRk5yZHJlOFpGeWxQU00zdHRSYTBTdHp3NW9PdklJek1qYlVyWU82T0JaSkkwMmdaTmluRWYzaDJfTGdKaEx4dUhUZmFoR3RtRzRjM2t5VS11OVpRLTY2dDlTNFdmUVlHSl9vbU5TLU5PWWdmemhjeTBTcWcwN1I5SXZPdktQYjFFNmp1eWw1UjEweTliUHBybWM1N05QT3g5ejFPWmpaeTBPeUw4S01TS2xxXzg1VFpiZzg2YzQ?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-06-16T15:30:09+00:00", "published_display": "16 Jun 2026 15:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck & Co. Inc. Stock (US58933Y1055): Valuation and fundamentals in focus after steady trading", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPU0EzMGdscUlvREhYNDBkbVF6S1kyVHA0dmJ1YW1ONFgyanZOSVNZc3VBY2RwQUtzR2tUN2Q4Y0k4SWxvc0ZIeXFEZHVkczRUZ3pTSGx4eUJuMG5FZi1IZEZmV1pXVE81S3lPVWNEY29QRlFGcHNCYTYzVmM0MWJYSHdKMkU3dVRCQjhET05waHNSdW41R1FtUE81MU1jdTJOM3dKeDNGNW5CXzBjNmFTVGdSMXRrajdnYnA0R2tWSzZlUQ?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-06-14T18:50:51+00:00", "published_display": "14 Jun 2026 18:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck (MRK) Stock After 53% One-Year Gain Is DCF Signaling Further Upside Potential", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxNSDlaTkQxdkN4NFl0YjZWeDhlVG01OERwcll1QThOVTA5c2UzNGs1Tl9oVDNyWGxyc2NWSTQ5OFk3NU5NTGxrUjNWWG5rekJ4dGo4WGNCN3VGLVZGeXBLdnltVXc0VFZoVzlXWTdncmNPdFUwWXpjWWFTYl9BNE93RERESHdXMkdTTWZnU3lSOFU?oc=5", "source_name": "Market source", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck & Co., Inc. Stock (US58933Y1055): Dow Jones Component Moves Higher In Thursday Trading", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQd1dmLWNTdEhiSHlxUU5kSWhaNEh5cUZrYlRDbmJxQ2ZLTWdvX084czhFVlZfVHEyUl9pUS1JOFB3a3VSWFRYZ2pvbWcwemk4NU55U0VvMXJxWU9TX2lqWk9jbFpHek9uMWctbG42MnBHS1pkdTlfSGtLZVVHYzJqMkVEa2Q3XzN3UU15LWhTclFEZ2NrcDdTa2s4eHVQWVNOcU04LU8zM0Y3WjBwY2ZBRmYwZm90QU80VVAxeg?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-06-11T17:44:04+00:00", "published_display": "11 Jun 2026 17:44", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck & Co., Inc. stock (US58933Y1055): Cancer portfolio drives growth amid patent and pricing quest", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxQOVR1SWltczJjTWt4NG81LTZrWmZGbUJLMmxGNk1tYkZ6T1RlMGo1SjdZNDktMU1pNDUwWVNmOWlYZkkyWUdudFE2ZzRYMldEcWQwWDNMdXo5MzdrVWMzRERaQlMtZFJDUFNTZW5PYVZCYnJ6MFFwazlSX0pEX1RCQ282a05mOWdmTmZVRTAyeXRiNnEtRWRpN2xEOTdybGhwRnNwV1ZfVU5PMFpDcDFpelk4ZDY4aklKX1VNVVJUYUQtQmc?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck & Co. stock (US58933Y1055): What investors are watching now", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNcDFaSmpiX2ppcFltMjdNYmlTY3hKZ05XUzltVldfWURiUk9PWkQ2ekZ1cmw3Z2ZpNzc1TUFJRV9tM1JvSDFqUjZwTWVrU251VFg2SXJkRnlZdXowby1iZnpLLW4wNDFFT0lwRVZ0WU5Tbk9qaU9lNWg5aUZtOHpnUjNNVGNOOXAxby1XVmhGTE1HSnE3V1FIbDhGUHBZNnNIQkNXcHNsQm5oR1I3OFBsNGJpX09Bb2JJZk1oWTJUSQ?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck & Co.: Why The Market Is Right To Start Buying Into Post-Keytruda Promise (NYSE:MRK)", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPdVNnNWNEV1N0X1N6YXJTT0w2SHNXcE1YZTZjbmRDV2RMd1hreG1jaGh3OXFZakplZ3RWY2JxcG1PbGNXQVcySWJ2V1dPRUZLUnpzSGMzcGdNNTlKRlJSWEMzZG1zM2tEdE1BVmVJeXpNOWtzSzVWV3VDTmNSTy1CSV9qRXZqUFozNGdiU3RTd1BiN1NzUXcyYjEzaHl0WWJ1cVV3QS1ydU9UUVF5cm9qejRMaUtLbUtsT284UQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Meet the Biotech Stock That's Trouncing Lilly, Merck, and Pfizer in 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQRzRaYk5Fa2YzREt0VGdGaDdMRExVX1BqUmtZSjROZkFhRktZMUNFb2xiRWRDWHNWSS1hWlRtajg2NS1MekpoZ0NPekVMWjhWd3ZLRlNwa1M1VWpubXpRWWV4Z0JFWDN5ZVlBTnhGZkFPd2J2YVlzUjg0dUd2MF9zNTlhV3lJMjVDbjdkWGQwaW1yR1gtQlpPYw?oc=5", "source_name": "The Motley Fool", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck & Co., Inc. stock (US58933Y1055): shares steady on NYSE as investors digest recent news flow", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQSk93QUpaVHplbi1CLTBVM25FUEE2U1BXUEhmdEpRQ2M3UVNMN04tTmMzaFZ3ZjVtVThTZFpsRzlqYkwtQkxoMUVWaHFwVlRWWi0wTy10WkstRTdFeElDMEhFSEZwdHRaUmIyWFJUQVpCWjFIMzFkSVhkTVFWWTVMX1BjLUx4WlUyY1l3djdZRlRSd0M3WTcyUjhhQzJaNmxuV2FhMHV0ZWVRVy1URE16emFzM0RKc0NaUXJz?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck Stock After a 60% Rally From Its Lows: Is It Still Worth Buying at $120?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPblVJMXc5SFdGYlZwZkNEdUl5RlIxTzlqYnFib0tKXzU0UmFxd1h1cEk0VUtJaWI1b2pzRlNUTVZDNlhtNlFReVFBUHpyemFYYmZQM1BuV2ZvVFpqakJsejd5TGhSSW9ncG0xWWRnemtIWmVVOHFqN1RzSzBIWktRSDl0b3J1akxaRFdDX2s3LWVHdTBKY1JDYU5lQk1PWDI0U2c?oc=5", "source_name": "TIKR.com", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Five-Year Tally: Merck Stock Delivers $47 Bil Gain", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQQUdPUjZtLV9rWVowSHhQQTlCQ3dTWXE1NmRMMERBazVka2hmTDJkODhNUDQ3dkhCVm1vZDZnelVjN2tGeDIwdUs2RzJWZ1loMng4ZWJfUXFfUXhuZnRDQXJXVXZla1UyWXBScjJvVk5CZnJidXFiYXBhQjhvb1Nmd25vZ3lsTVNWN0hmVEJaU0t6emFKTDNrODZPU2RjOVRUb19lRndkZ3UyZTJr?oc=5", "source_name": "Trefis", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck & Co. stock (US58933Y1055): A major patent update and product pipeline remain in focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQUUJJVkRjWERFV3laSFp2elRKTGQ4T0hXMGJuYmxCWlFvemlaNnJuamtZRlBEVVJIYWlMZ1FvVDdVZTQyZXRZbUJwRnotdk1oUUtXUUpTTnNjSDlyS0NUdzNONHJkTkFFVy1sT2xQbUJLWkdvNDhvNkRUdVlEd1QwSC1mWlUxMHN6R2Z6M1lsUm9zM3dmRzB2M2JRVWV6VTN3ekktTmlVU0hHTG1FUTlodFVQR1RsRVg1QUtrRm1MRWJydw?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck Stock Zooms Closer To A Breakout On 'A New Chapter' In Cancer", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOcFQ4QWZTdEF3QzFxYVZwTllCbElES2xTeXFzTWdpN1B5RVdpMmJPSVFfeWhIR3RoUUlkenUtMGtLcnFaak1XcFlaX3pRakJWZC1YOTFvWncwcGk4STZhVlFhcmE2SkJUOGRNUXRkTUp0akJUcjlBRUdLb3BDVzhHX0d0YTZ5WklJNlNyQmxURk40SDZLUDNqZXAtTUEyM0FKb1VfNldzdkU1b0pm?oc=5", "source_name": "Investor's Business Daily", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck Completes Acquisition of Terns Pharmaceuticals, Inc.", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNSTZWTWdvaHp2Zk16aFZ2TGdGUnBBZHR0TG0xbW1XckRma05aWmFkVFpFTFd5OFU3Tlh3U0JKMXV0Wk9SUlVacWptYUVnVXJ0RFViRnEtcENSdzRCcURmRUFiRURHTEs2NlQtVTFMRjNscmkyeVdaM2R3WGM0SkhJaFFnaUptaDg5VWZTMjJ1VXU0UVRzeUJQRGVVX1d2SDNDTnc5ZWQtaXBYNlZQaGZtdUFiVUQ?oc=5", "source_name": "Business Wire", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck Rises 11% YTD: Should Investors Buy, Sell or Hold the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPX202QklDZXVScVlBQ2w1ZVRVTk9uNVFPcXVkU2Z5VzRpWmxJT044aFpvMGdWS201Ul91TXRKM1NXS1JhTWIzV1A5LVNuSUFoaklEOVdlTWJ2R29WaDhoSDlnNkJMSHJpYWhWVjdaQmMxWWowemRaLXhzaGp0UjVyU0Z2QlFCSU5lb0E0SEt3QXRwVmphUV9FLVBWR1JWd1VaSzA0b09MOUpScjNxMWN6eDdTVlhUSVpiekE?oc=5", "source_name": "TradingView", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Merck (MRK) Shares Are Trading Lower Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOa2dWeTZvblFOdXpGRk0wUXhzQ2pIWU05dkYzQTY5em1ab2hsemRxRm1nb1lWdE9FbmJ5bUNHTTVDc2phdXZHTnFsanBiSUlxZTBBd1c3QmhiNzRRcEVacEduUENSS1c0OUtzcmtPX0huTHU3SXR6UVVyS2VvV0d4eFhvTmdvVlFnbUhCWmt2bUJYWXBZdW9kczlTbXFFUQ?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck (MRK) Stock Sinks As Market Gains: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxOZG9JMVV6ZkFFWm9lZTllT184YVFYTWVMNkNyQXhjRWt2dWIxWXQ4NDcyNmktaHhyX0dLRWhtRHBFaHA0bzNTVDllQ0l4eGdKcEtpSGFhVV9QLUV6LTVPemt6Tm9YVGJySkZSQ3F4enVLbGVBRW96ZUxGUXNoMURqZU12c0pSb1Z1cGJlWVNBbkU3RUhqNHdDVg?oc=5", "source_name": "Market source", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck (MRK) Stock Declines While Market Improves: Some Information for Investors", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNZ3htU2ZvamV2MUtPNWRxbk1KbGl1Z3ZNclkxQlJTZzd6RzdhaUFKNGdnU3JqRFFScllMLU5Gb3YxNkVWLUw5X0xCS3hGR0FkNGdtc1ZfSUxKZTU2NXNMODNXbjNtY05icFBhSFVKUmRnMjdYVER1YUZLYXNsOU5qU2ZZZVZOa01nc1FZTzM2bk0zNnFucnM1cE1Zdw?oc=5", "source_name": "Market source", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck CFO and R&D chief join TD Cowen health care fireside chat", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOcHRreDJJbDA3VUdkWDd6a3V5U2FUZkMyV2ZaeTUxOTN3bXNQUVkxSmNJWVRZNlhoeE82WlpNVmp1dnBneXN1dlpSakNndDliR05uSTdGWXBYdjBHaHlYR0FHYXBBVlVLMURQZWRlbWNVaHNRdEdSX2VwMVRwbEp5dDNPdUt5MVlCY0w2UjIxZ3BoQ3hVdGhtRVFDOEpyLU9jd1dBaGZBV3NnckdSMFFVMm9oN3c?oc=5", "source_name": "Stock Titan", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck & Company Stock Forecast 2026\u20132030 | Future Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMifkFVX3lxTE5MWktOSWJuTjNTbU1EZWVEUHlJeUdBNWc3ak9TN0RIMTFCQVRNZmpZdTRDMXl6aHhobXNoTTc0a0VNWGlhdno3RVlCVzdKazdmV3hxV1l3WTN4Tm9MeDQyY0UwbjJOWUtBUXdKbWtrSFBBZXdMSEF6UmNlQ3pBZw?oc=5", "source_name": "Capital.com", "published_at": "2026-02-18T08:00:00+00:00", "published_display": "18 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck Stock (MRK) Hitting Highs Into Earnings \u2013 Eyes On Breakout", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPU01ZWHVVLW9nUHQ3RDFuWmZrT3dmZ3VaNG1jWUNWanh6eGhlaWxmbkZ2X0JHX2NlZEg0ZEtsTHo4WTk0Ymc2Qm9CTml1U1dyNVdraFV5LXlPcGh1bDhZOFhILUZDdk9lVGNWdXpiY1FZODQtMFpGLTgzd2RFODlpRy1RU3FvdkJHWXVqRTRkUHo4NFNjVklSdnZ6dnNTUQ?oc=5", "source_name": "AskTraders", "published_at": "2026-02-03T08:00:00+00:00", "published_display": "03 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck to Complete Acquisition of Cidara Therapeutics", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNd0pqd3JNOVJxaDB2eUVZazhhZmJwc3REbGRZNUVrTGxqMFJIcFJJV0pzYlM5ODdQSUZiRnFOajRpeXRxS2lYWUJmNFIwLXkxN2hIMjhma0FwZjhhdzBVdlZ1R0RPYkpna2VXLTVDSVB0cmlXRW03Vk52ZTdlZlVMVGFkTTRYU2N3M0I5TnlaNGhKYllBLVBTSFFWWGxJUlJaUXM3X3VvUmNlaWsydEE?oc=5", "source_name": "Business Wire", "published_at": "2026-01-07T08:00:00+00:00", "published_display": "07 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here Are Thursday\u2019s Top Wall Street Analyst Research Calls: Digital Realty, GE Vernova, Micron Technology, Merck & Co., Rivian, United Airlines, and More", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAJBVV95cUxPS1AxVUZ2LU9jaURHWTNZM1ExTVVsQ3lmclhrQUFRSy15ckl2M3dhb0NPX05ZMVpJMzBnZVBCQXV6c041bERpcEI1SmlJVVpaMWNicjRDRkM5dl9NV3dHTWlCdTVrNzNyREo0OHpIQ3FjelBmYWdqNmtkM2d4ZktKYmNuTUhCNW1JSjByTkxfSFZ6bTdEanlMbDc1T3pJZGdncENuN3NfY1QzTlF5eGFucXdOOUtac3RMZjkzRFlWczB3b0lra0tRMEVQTlEwS0pwYnNWMlU2Z0QtMjk5TTlnNml6ZWtoeHFfNzlhUWxIVmx3Mmkwa25WNDZ4ckptMFQybkFVdWFSTXhPQjZOY2tkNjB3Mko?oc=5", "source_name": "24/7 Wall St.", "published_at": "2025-12-18T08:00:00+00:00", "published_display": "18 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stock of the Week - Merck & Co Inc (23.10.2025)", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQN2FBUlJkQ1F2dWJXRURMWmlONDlzZDg5bUZudC1SZFlJdzhBLVRiOHREcnZ6Q1JQQ1JZb1plUW5UNGJjQWpKYTNiTDVuREJpRENuLTZxWG15RkhJLURzZktJX3lpRUdvWDV1OVFaaERIZGdGaFp5eHRxMWlHM2tlUm1kRENFUGE3NC1RZjhRUVRLMnFlb1NOQkdzd2d3dWNG?oc=5", "source_name": "XTB.com", "published_at": "2025-10-23T07:00:00+00:00", "published_display": "23 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": [{"title": "Alignment Healthcare And 2 Other Stocks That May Be Trading Below Estimated Value", "summary": "This article highlights three US stocks\u2014Alignment Healthcare (ALHC), Ouster (OUST), and Tutor Perini (TPC)\u2014that are identified as potentially undervalued based on cash flow analysis. It provides an overview of each company, their estimated discount to fair value, revenue and earn", "url": "https://simplywall.st/stocks/us/capital-goods/nyse-tpc/tutor-perini/news/alignment-healthcare-and-2-other-stocks-that-may-be-trading/amp", "source_name": "Simply Wall Street", "published_at": "2026-06-18T11:39:15", "published_display": "18 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "sector", "tier_label": "Sector context"}]}, "total_fetched": 113, "total_relevant": 49, "sentiment_summary": {"positive": 17, "negative": 4, "neutral": 28, "score": 55, "total": 49, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 80, "events": [{"event": "general", "label": "Market update", "weight": 16.45, "count": 28}, {"event": "earnings", "label": "Earnings", "weight": 4.15, "count": 8}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 3.45, "count": 5}, {"event": "deals", "label": "Deals and strategy", "weight": 2.2, "count": 4}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 17, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 113.87, "latest_week": "2026-06-19", "one_week_move": -3.5, "four_week_move": -6.1, "twelve_week_move": -4.0, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": -0.329438, "market_dynamics_buy_signal": false, "relative_strength": 3.436845, "fair_value_gap": 13.8, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 46.7511, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-3.5% over one week, -6.1% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 64, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "AD HOC NEWS", "count": 11}, {"label": "Market source", "count": 6}, {"label": "Seeking Alpha", "count": 3}, {"label": "Business Wire", "count": 3}, {"label": "Benzinga", "count": 2}, {"label": "Trefis", "count": 2}, {"label": "Stock Titan", "count": 2}, {"label": "Citeline News & Insights", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 48}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 1}], "events": [{"label": "Market update", "count": 28}, {"label": "Earnings", "count": 8}, {"label": "Regulatory and legal", "count": 5}, {"label": "Deals and strategy", "count": 4}, {"label": "Analyst action", "count": 3}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "80/100 classification confidence."}, {"label": "Company focus", "value": "48", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "5", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-3.5% over one week, -6.1% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Merck Expands TL1A Lead With Positive Tulisokibart Results In UC"}], "updated_at": "2026-06-22T22:44:39.214695+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}